Merck's 15-strain pneumonia shot matches Prevnar 13 in late-stage infant study, but Pfizer's next-gen shot looms
In order to keep the heat on Pfizer and its next-generation pneumococcal vaccine, Merck knows it will need to get creative to give its 15-serotype shot a fighting chance. Infant patients could hold the key, and new data continue to support Merck’s case there.
Merck’s Vaxneuvance, a next-gen, 15-valent shot, matched Pfizer’s blockbuster Prevnar 13 in terms of driving immunogenicity across 13 shared serotypes and on the safety front, according to data from the Phase III PNEU-PED study revealed Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.